This pilot phase II trial studies how well fludeoxyglucose F-18 positron emission tomography (PET) works in planning radiation therapy in participants with cervical, vulvar, esophageal, or anal canal cancer. Using (PET) in addition to the standard computed tomography to plan radiation therapy for cancer may help doctors to maximize the dose to the cancer and minimize the dose to normal tissues.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03403465.
PRIMARY OBJECTIVE:
I. To explore the prognostic importance of intra-treatment functional imaging on clinical relevant tumor endpoints (i.e. progression-free survival, pathologic complete response) among patients with gastrointestinal and gynecologic cancers being treated with radiation therapy (RT).
SECONDARY OBJECTIVE:
I. To further evaluate the impact on, and potential sparing of, critical normal tissues with intra-treatment PET based re-planning for radiation therapy among patients with gastrointestinal and gynecologic cancers being treated with RT.
EXPLORATORY OBJECTIVE:
I. To evaluate the predictive value of functional imaging for bone marrow response to radiation therapy, and acute/late toxicity.
OUTLINE:
Within 1-2 weeks prior to the start of any sequential boost plans, participants receive fludeoxyglucose F-18 intravenously (IV), and within 50-70 minutes, participants undergo PET.
Lead OrganizationDuke University Medical Center
Principal InvestigatorJunzo Paul Chino
